Literature DB >> 22162466

The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center.

Rossella Elisei1, Cristina Romei, Giulia Renzini, Valeria Bottici, Barbara Cosci, Eleonora Molinaro, Laura Agate, Virginia Cappagli, Paolo Miccoli, Piero Berti, Pinuccia Faviana, Clara Ugolini, Fulvio Basolo, Paolo Vitti, Aldo Pinchera.   

Abstract

BACKGROUND: Medullary thyroid carcinoma (MTC) is a calcitonin (CT)-producing C-cell tumor. In hereditary cases, a germline RET mutation is found in 98% of families. Because MTC is cured only if intrathyroidal, prophylactic thyroidectomy is recommended in the gene carrier (GC). AIMS: The aim was to determine whether thyroidectomy performed when stimulated CT becomes detectable is as safe as prophylactic thyroidectomy and to identify the serum CT cutoff able to distinguish intrathyroidal from extrathyroidal MTC. PATIENTS: Eighty-four GC were prospectively enrolled; 53 of the 84 underwent total thyroidectomy, one refused surgery, and 30 with normal basal and stimulated CT were under surveillance. The follow-up ranged from 2 to 18 yr.
RESULTS: GC operated on for elevated stimulated CT included 27 GC with a positive peak CT at the screening and four cases who became positive after 4 yr. All of them had intrathyroidal MTC and no node metastases; all were cured after a mean follow-up of 7.5 yr. Among those operated on for detectable basal CT, intrathyroidal tumors were found when CT was below 60 pg/ml, whereas either node metastases or larger tumors were observed when CT was above 60 pg/ml. No correlation among serum CT, age, and type of RET mutation was observed. Thirty GC were still biochemically negative at the annual control.
CONCLUSIONS: The time of thyroidectomy in GC with negative CT could be personalized and safely planned when stimulated CT becomes positive, independent of the type of RET mutation and patient's age. In this series, a basal CT below 60 pg/ml was always associated to an intrathyroidal localization of MTC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22162466     DOI: 10.1210/jc.2011-2046

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

Review 1.  Management of hereditary medullary thyroid carcinoma.

Authors:  Theodora Pappa; Maria Alevizaki
Journal:  Endocrine       Date:  2016-02-02       Impact factor: 3.633

Review 2.  How does genome sequencing impact surgery?

Authors:  Marlies S Reimers; Charla C Engels; Peter J K Kuppen; Cornelis J H van de Velde; Gerrit J Liefers
Journal:  Nat Rev Clin Oncol       Date:  2014-06-24       Impact factor: 66.675

3.  The RET C611Y mutation causes MEN 2A and associated cutaneous lichen amyloidosis.

Authors:  Xiao-Ping Qi; Jian-Zhong Peng; Xiao-Wei Yang; Zhi-Lie Cao; Xiu-Hua Yu; Xu-Dong Fang; Da-Hong Zhang; Jian-Qiang Zhao
Journal:  Endocr Connect       Date:  2018-07-26       Impact factor: 3.335

Review 4.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

5.  Failure of pentagastrin-stimulated calcitonin testing in early manifestation of familial medullary thyroid cancer.

Authors:  Christian Pirich; Gundula Rendl; Cornelia Hauser-Kronberger; Ingrid Häusler
Journal:  Wien Klin Wochenschr       Date:  2012-09-11       Impact factor: 1.704

6.  The rare intracellular RET mutation p.S891A in a Chinese Han family with familial medullary thyroid carcinoma.

Authors:  Xiao-Ping Qi; Rong-Xin Zhang; Jin-Lin Cao; Zhen-Guang Chen; Hang-Yang Jin; Ren-Rong Yang
Journal:  J Biosci       Date:  2014-06       Impact factor: 1.826

7.  2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer.

Authors:  R Elisei; M Alevizaki; B Conte-Devolx; K Frank-Raue; V Leite; G R Williams
Journal:  Eur Thyroid J       Date:  2012-12-19

8.  Ultrasonography should not guide the timing of thyroidectomy in pediatric patients diagnosed with multiple endocrine neoplasia syndrome 2A through genetic screening.

Authors:  Lilah F Morris; Steven G Waguespack; Beth S Edeiken-Monroe; Jeff E Lee; Thereasa A Rich; Anita K Ying; Carla L Warneke; Douglas B Evans; Nancy D Perrier; Elizabeth G Grubbs
Journal:  Ann Surg Oncol       Date:  2012-08-14       Impact factor: 5.344

Review 9.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

10.  Timing and extent of thyroid surgery for gene carriers of hereditary C cell disease--a consensus statement of the European Society of Endocrine Surgeons (ESES).

Authors:  Bruno Niederle; Frédéric Sebag; Michael Brauckhoff
Journal:  Langenbecks Arch Surg       Date:  2013-12-03       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.